Canaccord Genuity Analysts Give Aldeyra Therapeutics, Inc. (ALDX) a $12.00 Price Target
Other equities research analysts have also issued reports about the stock. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the stock a buy rating in a report on Saturday, April 1st. Cowen and Company reaffirmed a buy rating and issued a $20.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, March 31st. Zacks Investment Research raised shares of Aldeyra Therapeutics from a hold rating to a buy rating and set a $5.50 target price for the company in a research report on Friday, March 24th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $16.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, May 31st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $14.30.
Aldeyra Therapeutics (ALDX) opened at 4.45 on Wednesday. The stock’s 50 day moving average is $4.56 and its 200 day moving average is $4.91. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $8.19. The stock’s market capitalization is $27.79 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. Analysts forecast that Aldeyra Therapeutics will post ($1.52) EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $132,000. Hikari Power Ltd purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $188,000. Geode Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 3.6% in the first quarter. Geode Capital Management LLC now owns 54,888 shares of the biotechnology company’s stock worth $274,000 after buying an additional 1,912 shares during the period. Sabby Management LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $898,000. Finally, Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 102.9% in the first quarter. Vanguard Group Inc. now owns 295,226 shares of the biotechnology company’s stock worth $1,476,000 after buying an additional 149,754 shares during the period. 58.25% of the stock is owned by institutional investors.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.